Cargando…

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)

Detalles Bibliográficos
Autores principales:	Ko, Jihee, Moon, Sun Joon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404527/ https://www.ncbi.nlm.nih.gov/pubmed/37533199 http://dx.doi.org/10.4093/dmj.2023.0164

Ejemplares similares

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
por: Lin, Tzu-Yi, et al.
Publicado: (2023)

Safety of COVID-19 Vaccines among Patients with Type 2 Diabetes Mellitus: Real-World Data Analysis (Diabetes Metab J 2023;47:356-65)
por: Kim, Hye Jun, et al.
Publicado: (2023)

Safety of COVID-19 Vaccines among Patients with Type 2 Diabetes Mellitus: Real-World Data Analysis (Diabetes Metab J 2023;47:356-65)
por: Ohn, Jung Hun
Publicado: (2023)

Association of Body Mass Index and Fracture Risk Varied by Affected Bones in Patients with Diabetes: A Nationwide Cohort Study (Diabetes Metab J 2023;47:242-54)
por: Park, So Young
Publicado: (2023)

Association of Body Mass Index and Fracture Risk Varied by Affected Bones in Patients with Diabetes: A Nationwide Cohort Study (Diabetes Metab J 2023;47:242-54)
por: Lee, Se-Won, et al.
Publicado: (2023)

Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography (Diabetes Metab J 2023;47:104-17)
por: Roh, Eun
Publicado: (2023)

Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography (Diabetes Metab J 2023;47:104-17)
por: Kim, Hwi Seung, et al.
Publicado: (2023)

Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
por: Lee, Da Young
Publicado: (2023)

Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
por: Scherbak, Nikolai N., et al.
Publicado: (2023)

Letter: Features of Long-Standing Korean Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy: A Study Based on Standardized Clinical Data (Diabetes Metab J 2017;41:393-404)
por: Yun, Jae-Seung
Publicado: (2017)

Response: Features of Long-Standing Korean Type 2 Diabetes Mellitus Patients with Diabetic Retinopathy: A Study Based on Standardized Clinical Data (Diabetes Metab J 2017;41:393-404)
por: Rhee, Sang Youl, et al.
Publicado: (2017)

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
por: Lin, Tzu-Yi, et al.
Publicado: (2023)

Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658–62)
por: Kim, Hwi Seung, et al.
Publicado: (2022)

Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study (Diabetes Metab J 2022;46: 658–62)
por: Kawada, Tomoyuki
Publicado: (2022)

Correction to “Glucagon-like Peptide-1 Receptor Agonist Treatment With Semaglutide in Type 1 Diabetes” (J Clin Endo Metab Case Reports. 2023; 1(1): 10.1210/jcemcr/luac017)
Publicado: (2023)

Letter: Diabetic Retinopathy and Endothelial Dysfunction in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2013;37:262-9)
por: Son, Seok Man
Publicado: (2013)

Response: Diabetic Retinopathy and Endothelial Dysfunction in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2013;37:262-9)
por: Yun, Jae-Seung, et al.
Publicado: (2013)

Letter: Clinical Course and Risk Factors of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus in Korea (Diabetes Metab J 2016;40:482-93)
por: Kim, Nam Hoon
Publicado: (2017)

Response: Clinical Course and Risk Factors of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus in Korea (Diabetes Metab J 2016;40:482-93)
por: Yun, Jae-Seung, et al.
Publicado: (2017)

Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies
por: Zheng, Deqiang, et al.
Publicado: (2023)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

The effect of sodium‐glucose cotransporter 2 inhibitors and glucagon‐like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes
por: Dey, Amit K., et al.
Publicado: (2019)

Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment
por: Hiramatsu, Takeyuki, et al.
Publicado: (2020)

Letter: Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus (Diabetes Metab J 2013;37:423-8)
por: Beyan, Cengiz, et al.
Publicado: (2014)

Response: Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus (Diabetes Metab J 2013;37:423-8)
por: Kim, Jin Hwa, et al.
Publicado: (2014)

Lost in Translation? Measuring Diabetic Neuropathy in Humans and Animals (Diabetes Metab J 2021;45:27-42)
por: Fustes, Otto Jesus Hernandez
Publicado: (2021)

Lost in Translation? Measuring Diabetic Neuropathy in Humans and Animals (Diabetes Metab J 2021;45:27-42)
por: Jin, Heung Yong, et al.
Publicado: (2021)

The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes
por: Kim, Gwang Sil, et al.
Publicado: (2019)

SUN-618 Decision Analysis for Glucagon-Like Peptide Receptor Agonists vs. Sodium-Glucose cotransporter2 Inhibitors in Type 2 Diabetes Mellitus
por: khazaali, Ali Al, et al.
Publicado: (2020)

Cardiovascular outcomes with glucagon-like peptide 1 agonists and sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes: A meta-analysis
por: Lee, Yeong-Min, et al.
Publicado: (2022)

Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Evidence‐based comparison of glucagon‐like peptide receptor agonists and sodium–glucose cotransporter 2 inhibitors
por: Watada, Hirotaka
Publicado: (2019)

Patients’ Preferences for Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
por: Banjara, Bidur, et al.
Publicado: (2022)

Letter: Diabetic Polyneuropathy and Cardiovascular Complications in Type 2 Diabetic Patients (Diabetes Metab J 2011;35:390-6)
por: Ko, Sun-Hye, et al.
Publicado: (2011)

Re: Daniel D. Joyce, Matteo Soligo, Alessandro Morlacco, et al. Effect of Preoperative Multiparametric Magnetic Resonance Imaging on Oncologic and Functional Outcomes Following Radical Prostatectomy. Eur Urol Open Sci 2023;47:87–93
por: Tandogdu, Zafer, et al.
Publicado: (2023)

The Safety Profile of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide 1 Receptor Agonists in the Standard of Care Treatment of Type 2 Diabetes Mellitus
por: Salmen, Teodor, et al.
Publicado: (2023)

Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM
por: McKee, Alexis, et al.
Publicado: (2020)

Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes
por: Essien, Utibe R., et al.
Publicado: (2023)

394 Desensitization Protocol to Methotrexate
por: Maya, Jonathan, et al.
Publicado: (2012)

Letter: The Risk of Bladder Cancer in Korean Diabetic Subjects Treated with Pioglitazone (Diabetes Metab J 2012;36:371-8)
por: Li, Sheyu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6pua7qnvlvh4di5tcfjlaii7em